COGNITION THERAPEUTICS INC
CGTXNasdaq
$0.96
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +55.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$85.7M
Enterprise Value
$54.6M
P/E
—
P/S
—
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-65.5%
ROIC
—
Debt / Equity
—
Net Cash
$31.1M
Return 1Y
+41.3%
Company profile
Cognition Therapeutics, Inc. engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease.
- CEO
- Lisa R. Ricciardi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New York
- Website
- cogrx.com
Management & directors
- Doyle John BrendanChief Financial Officer
- Caggiano AnthonyChief Medical Officer
- Ricciardi LisaCEO & President
Roles derived from SEC Form 4 filings.
Earnings
CGTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.05↓ -64.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$17.4M | -$28.6M | -$43.6M | -$50.7M | -$54.0M | -$47.8M |
| Net income | -$7.8M | -$11.7M | -$21.4M | -$25.8M | -$34.0M | -$23.5M |
| Diluted EPS | -$23.76 | -$3.13 | -$0.91 | -$0.86 | -$0.86 | -$0.32 |
| Operating cash flow | -$3.4M | -$3.6M | -$18.5M | -$16.0M | -$28.5M | -$24.6M |
| Free cash flow | -$3.4M | -$3.7M | -$18.7M | -$16.2M | -$28.5M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.7M | -$14.5M | -$10.7M | -$13.8M | -$14.0M | -$6.4M | -$13.7M | -$8.8M |
| Net income | -$7.0M | -$9.9M | -$7.8M | -$8.5M | -$6.7M | -$4.9M | -$3.3M | -$4.6M |
| Diluted EPS | -$0.18 | -$0.25 | -$0.16 | -$0.14 | -$0.11 | -$0.06 | -$0.01 | -$0.05 |
| Operating cash flow | -$6.0M | -$6.9M | -$8.4M | -$9.9M | -$5.6M | -$5.7M | -$3.4M | -$5.5M |
| Free cash flow | — | -$6.9M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
- 26d agoCognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%stocktwits.com
- 26d agoCognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)investorshub.advfn.com
- 26d agoCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Khattar Jack A. | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-06-17 | Monia Brett P | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-06-17 | Wallace Peggy | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-06-17 | RICHSTONE ELLEN B | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-06-17 | Fletcher Aaron G.L. | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-05-01 | Doyle John Brendan· Chief Financial Officer | Tax withholding | 8,567 | $1.28 | $10,965.76 | filing |
| 2026-04-16 | Doyle John Brendan· Chief Financial Officer | Buy | 10,000 | $1.13 | $11,300.00 | filing |
| 2026-04-16 | Caggiano Anthony· Chief Medical Officer | Buy | 10,000 | $1.11 | $11,100.00 | filing |
| 2026-04-16 | Ricciardi Lisa· CEO & President | Buy | 9,175 | $1.10 | $10,092.50 | filing |
| 2026-02-15 | Ricciardi Lisa· CEO & President | Tax withholding | 5,850 | $1.12 | $6,552.00 | filing |
| 2026-02-15 | Caggiano Anthony· Chief Medical Officer | Tax withholding | 4,680 | $1.12 | $5,241.60 | filing |
| 2026-02-15 | Doyle John Brendan· Chief Financial Officer | Tax withholding | 1,560 | $1.12 | $1,747.20 | filing |
| 2026-02-04 | Ricciardi Lisa· CEO & President | Tax withholding | 51,704 | $1.03 | $53,255.12 | filing |
| 2026-02-04 | Doyle John Brendan· Chief Financial Officer | Tax withholding | 26,921 | $1.03 | $27,728.63 | filing |
| 2026-02-04 | Caggiano Anthony· Chief Medical Officer | Tax withholding | 26,919 | $1.03 | $27,726.57 | filing |
| 2026-02-03 | Ricciardi Lisa· CEO & President | Tax withholding | 26,036 | $1.12 | $29,160.32 | filing |
| 2026-02-03 | Caggiano Anthony· Chief Medical Officer | Tax withholding | 11,488 | $1.12 | $12,866.56 | filing |
| 2026-02-03 | Ricciardi Lisa· CEO & President | Award | 800,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Doyle John Brendan· Chief Financial Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Caggiano Anthony· Chief Medical Officer | Award | 400,000 | $0.00 | $0.00 | filing |
| 2025-12-18 | Ricciardi Lisa· CEO & President | Tax withholding | 23,400 | $1.50 | $35,100.00 | filing |
| 2025-12-18 | Caggiano Anthony· Chief Medical Officer | Tax withholding | 20,280 | $1.50 | $30,420.00 | filing |
| 2025-12-18 | Doyle John Brendan· Chief Financial Officer | Tax withholding | 9,360 | $1.50 | $14,040.00 | filing |
| 2025-12-18 | Caggiano Anthony· Chief Medical Officer | Award | 65,000 | $0.00 | $0.00 | filing |
| 2025-12-18 | Doyle John Brendan· Chief Financial Officer | Award | 30,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.